Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614734 | 0.92 | CHRNA7 (0.66) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL16006990 | 0.92 | CHRNA7 (0.66) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL16007093 | 0.85 | CHRM3 (0.42) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL29384752 | 0.79 | HRH3 (0.38) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL29386768 | 0.78 | HRH3 (0.42) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL16007179 | 0.78 | CHRNA7 (0.59) | CHRNA7BCHEACHECHRM3GAA | |
| SCHEMBL29387657 | 0.77 | HRH3 (0.38) | NTMT1 | |
| SCHEMBL16007046 | 0.77 | CHRM3 (0.51) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL30745971 | 0.77 | CHRM3 (0.51) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL16007049 | 0.77 | CHRM3 (0.51) | CHRNA7BCHEACHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673906-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2020-02-13 | — | — | US | disclosed |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-9139580-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9126993-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2014-12-18 | — | — | US | disclosed |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRNA7 4678/4885BCHE 905/4885ACHE 3823/4885 |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRNA7 4670/4885BCHE 869/4885ACHE 3743/4885 |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRNA7 4670/4885BCHE 869/4885ACHE 3743/4885 |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRNA7 4670/4885BCHE 869/4885ACHE 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.